Stamlo D

Quick links to important sections

Stamlo D

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stamlo D

Property Description
Active Ingredients Amlodipine, Hydrochlorothiazide
Form Oral Tablet
Pharmacological Class Antihypertensive, Calcium Channel Blocker (CCB) and Thiazide Diuretic Combination
Common Use Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Stamlo D?

Stamlo D is defined as a fixed-dose combination medication classified within the overarching category of antihypertensive drugs, specifically designed for the treatment of hypertension in adults. It is supplied as an oral tablet and is entirely of synthetic origin. This therapeutic approach, combining two agents with distinct mechanisms, is clinically recognized for its capacity to improve treatment adherence and efficacy compared to administering the components as separate tablets. Combining antihypertensive agents with different mechanisms, such as a Calcium Channel Blocker and a diuretic, is an established strategy for optimizing blood pressure reduction.

What is the Composition of Stamlo D?

The formulation of Stamlo D integrates two distinct active ingredients: Amlodipine and Hydrochlorothiazide. Amlodipine is a Calcium Channel Blocker (CCB) that aids in widening blood vessels, while Hydrochlorothiazide functions as a Thiazide diuretic, which helps the body reduce excess fluid. This pairing of a vasodilator and a volume-reducing agent is a defining characteristic of this combination. Combination therapies that include both dihydropyridines (like Amlodipine) and diuretics (like Hydrochlorothiazide) are utilized for their synergistic effects.

What is the General Purpose of Combining Amlodipine and Hydrochlorothiazide?

The primary general purpose of this specific pairing is to achieve sustained blood pressure control through its dual-action mechanism. This approach leverages the component actions—vasodilation and diuresis—to systematically reduce both peripheral vascular resistance and blood volume. This systematic reduction is designed to alleviate chronic strain on the cardiovascular system, providing a comprehensive solution often targeted at individuals whose hypertension requires the simultaneous action of multiple drug classes.

Regulatory References

  1. Hydrochlorothiazide: MedlinePlus Drug Information

What side effects are possible with Stamlo D?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Amlodipine/Hydrochlorothiazide as documented in official government regulatory labels.

Regulatory Classification of Common Adverse Reactions

The safety profile is characterized by events officially categorized as Common (occurring in ge2% of patients in clinical trials). These include peripheral edema (swelling), headache, dizziness, fatigue, and nasopharyngitis. Adverse effects are formally mapped to physiological domains, affecting the Vascular, Nervous System, Metabolism, and Musculoskeletal system-organ classes.

Serious Adverse Reactions and Safety Constraints

The regulatory documents define several serious safety constraints. The medicine is contraindicated in patients with Anuria (inability to pass urine) and in those with hypersensitivity to sulfonamide-derived drugs (due to the Hydrochlorothiazide component).

Serious reactions listed in official warnings include the risk of Fetal Toxicity, requiring avoidance during pregnancy, and the potential for Acute Myocardial Infarction or increased angina, particularly upon initiation or dosage increase of the amlodipine component. The label also notes that the hydrochlorothiazide component is associated with the risk of Acute Myopia and Secondary Angle Closure Glaucoma.

Population and Exposure-Related Safety Patterns

Official safety statements advise caution or avoidance in specific populations: individuals with severe renal impairment and severe hepatic impairment require close monitoring or alternative therapy, as noted in the label. Furthermore, the risk of Non-melanoma skin cancer is associated with long-term exposure and cumulative doses of the hydrochlorothiazide component, a pattern explicitly documented in regulatory data.

Overdose and Emergency Response

The official regulatory profile for an overdose of Amlodipine/Hydrochlorothiazide describes two primary physiological outcomes: excessive vascular effects from Amlodipine and fluid and electrolyte depletion from Hydrochlorothiazide.

Documented Overdose Presentations

Overdose manifestations primarily include signs of marked and prolonged systemic hypotension due to excessive vasodilation. The diuretic component may cause severe hypokalemia and hyponatremia, leading to symptoms such as lethargy, muscle cramps, vomiting, and dehydration. These disturbances define a high-level severity risk, as regulatory documents cite the potential for progression to profound hypotension, shock, cardiac arrhythmias, or seizures.

Required Emergency Actions

Official emergency instructions mandate that one must seek immediate medical attention for any suspected overdose. Emergency services should be contacted immediately if the individual has collapsed, had a seizure, has trouble breathing, or is unresponsive.

There is no specific antidote known for the Amlodipine component. Management is strictly symptomatic and supportive, which includes the administration of intravenous fluids and, if required, a vasoconstrictor. Gastric lavage may be considered. Continuous monitoring of cardiac function and serum electrolytes is explicitly required for observation. For patients with hepatic impairment, minor electrolyte changes carry the documented risk of precipitating hepatic coma.

Therapeutic Uses of Stamlo D

What Stamlo D Treats: Main Uses and Benefits

This combination therapy is commonly used for the long-term management of High Blood Pressure (Hypertension), and is relevant when supportive symptom management is appropriate. The medication is used for the treatment of hypertension to lower blood pressure, assisting with the management of long-term cardiovascular risks and helping to address symptoms that create noticeable physiological strain.

Symptom Support and Functional Stability

The medication is generally applied in settings where patients experience symptoms related to systemic imbalance and heightened physiological activity. It is relevant for easing symptoms related to Excess Fluid Accumulation or generalized swelling (edema) that can often accompany high blood pressure. This supports the patient during difficult episodes by easing distress and assists with maintaining functional stability related to fluid balance. It is commonly used to help with managing conditions such as hypertension and fluid retention.

Symptom Support
Noticeable Physiological Strain

“The dual action helps the patient cope more steadily and assists with maintaining functional stability.”

Regulatory References

  1. NIH DailyMed drug label

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Stamlo D? — Official Regulatory Information

This section defines the eligible and non-eligible populations for the Amlodipine/Hydrochlorothiazide combination based strictly on government regulatory documents.

Category Official Regulatory Statement
Populations for whom use is allowed: Adult patients (aged 18 years and older) are the approved population for the treatment of hypertension.
Populations for whom use is not recommended: Pediatric patients (under 18 years of age) and women who are breastfeeding; Pregnant women in the first trimester (use is advised against).
Populations for whom use is contraindicated: Patients with Hypersensitivity to Amlodipine, Hydrochlorothiazide, or any sulphonamide-derived drugs. Use is prohibited in patients with Anuria (no urine output) or severe renal impairment (GFR <30 mL/min/1.73 m^2). Contraindications also apply to patients with severe hepatic impairment, severe hypotension, shock, or certain refractory electrolyte disturbances.
Age-related eligibility rules: Safety and effectiveness in the pediatric population are not established, leading to a not recommended status. Older adults require caution and close monitoring.
Condition-specific eligibility rules: The medicine is contraindicated in severe hepatic impairment and severe renal impairment. Use is contraindicated in the second and third trimesters of pregnancy due to the officially documented risk of fetal toxicity.

Connection to the overall eligibility profile: Regulatory documents define eligibility through a framework of absolute contraindications for high-risk groups (such as those with severe organ failure or drug hypersensitivity) and a not recommended status for populations lacking sufficient safety data (such as children). Conditional use is defined for other groups, such as those with volume depletion, requiring correction before initiation.

What should I know about interactions with other medicines?

The official regulatory profile for Stamlo D (Amlodipine and Hydrochlorothiazide) documents specific interactions concerning both components, resulting in formalized constraints on co-administration.

Official Combination Constraints

  • Contraindicated Combinations: The medicine is formally prohibited for use in patients with Anuria or those with known hypersensitivity to sulfonamide-derived drugs (due to the Hydrochlorothiazide component).

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interactions are officially categorized based on altered drug levels or reinforced effects:

  • Exposure-Altering Restriction: Amlodipine causes a pharmacokinetic interaction with Simvastatin, officially requiring the co-administered dose of Simvastatin to be limited to 20 mg daily.
  • Toxicity Risk: The Hydrochlorothiazide component reduces the renal clearance of Lithium, which is officially documented as increasing the risk of Lithium toxicity. Careful monitoring of serum concentration is required.
  • Enzyme Effects: Strong and moderate CYP3A Inhibitors are associated with increased systemic exposure of Amlodipine. Conversely, CYP3A Inducers may decrease Amlodipine plasma concentrations, requiring monitoring.
  • Additive Hypotension: Co-administration with Alcohol, Barbiturates, Narcotics, or Antidepressants is documented to potentiate the risk of orthostatic hypotension.
  • Other Interactions: NSAIDs may reduce the anti-hypertensive effect and increase the risk of renal impairment. Grapefruit or Grapefruit Juice may also increase Amlodipine absorption, leading to excessive blood pressure lowering.

Mechanism of Action

Stamlo D is a fixed-dose combination containing Amlodipine and Hydrochlorothiazide, modulating systemic vascular resistance and plasma volume via distinct mechanisms.

Amlodipine is a dihydropyridine calcium channel blocker. Its primary biological target is the voltage-dependent L-type calcium channel, predominantly in the peripheral arterial smooth muscle cells. Amlodipine functions as a slow-channel inhibitor, reducing the transmembrane influx of extracellular calcium ions. This reduction in intracellular calcium concentration attenuates the interaction between calcium and calmodulin, preventing the activation of myosin light-chain kinase. The consequence is reduced phosphorylation of myosin light chain and decreased vascular smooth muscle contractility, leading to direct peripheral arterial vasodilation and a subsequent reduction in total peripheral resistance.

Hydrochlorothiazide is a thiazide diuretic. It acts on the distal convoluted tubule of the kidney as an inhibitor of the Na^+/ Cl^- symporter. This molecular interaction prevents the reabsorption of approximately 5-10% of filtered sodium and chloride ions. The increased delivery of Na^+ and water to the collecting duct results in an increased urinary output of water and electrolytes, primarily Na^+ and Cl^-, leading to a reduction in plasma volume and decreased cardiac preload. The combined effect of reduced total peripheral resistance and decreased plasma volume modulates systemic pressure.

Dosage and Administration Information

How to Use Stamlo D

Stamlo D is a fixed-dose combination medication containing Amlodipine and Hydrochlorothiazide (HCTZ) that is administered for combination antihypertensive therapy. The combination tablet is not indicated for the initial treatment of hypertension; its use is reserved for replacement therapy or add-on therapy for patients whose blood pressure is not adequately controlled on single-agent or dual-agent regimens.


Dosing and Administration Protocol

Feature General Administration Instruction
Route and Frequency Taken orally as a single tablet once daily.
Intake Condition The tablet may be administered with or without food.
Dosing Strengths Fixed-dose strengths typically range from Amlodipine 5 mg to 10 mg combined with HCTZ 12.5 mg to 25 mg. The maximum recommended daily component doses in fixed-dose products are typically Amlodipine 10 mg and HCTZ 25 mg.
Dose Adjustment Interval The dose may be increased only after a minimum of two weeks of therapy to allow the full therapeutic effect to manifest before any adjustment.

Usage in Specific Populations

Clinical considerations include specific cautions for certain patient groups:

  • Renal Impairment: The fixed combination is not recommended for use in patients with severe reduction in kidney function (creatinine clearance le 30 mL/min).
  • Hepatic Impairment: Use requires caution, and lower doses of the Amlodipine component may be considered due to decreased clearance in patients with liver insufficiency.

Recent Clinical Evidence

Research evidence / Overview of Studies for Stamlo D

Evidence for Use in Managing High Blood Pressure (Hypertension)

The Amlodipine/Hydrochlorothiazide combination was evaluated in research settings examining high blood pressure (hypertension), a condition where research monitored outcomes related to physiological strain. The available research is heavily based on Randomized Controlled Trials (RCTs), where participants are randomly assigned to study groups. These studies primarily monitored short-term changes in blood pressure readings, such as Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), to measure how these values evolved in the observed populations. Findings describe patterns observed in the studies, often reporting the proportion of patients who achieved specific blood pressure targets over the study period.

### Comparative Research Against Monotherapy and Other Agents

Many trials examined the dual-action combination by comparing it directly to its component drugs when taken alone (monotherapy). Studies have also explored how the combination was observed in comparison to other classes of blood pressure medications or different dual-therapy pairings. These comparative studies explored numerical differences in measured changes in SBP and DBP between the groups, and this was observed in the trials that focused on these endpoints. These studies often focus on short-term data, with typical follow-up durations were limited to about eight to sixteen weeks.

Evidence in Specific Patient Groups and Comorbidities

The combination was evaluated in specific populations. Research was studied for use in older adults and in patients with co-occurring conditions, notably Type 2 Diabetes Mellitus, which are conditions marked by functional limitations. Some studies have also specifically included or analyzed data for different racial or ethnic groups, to see how data show patterns related to blood pressure changes across these varied groups. Research was studied for how these patterns may differ depending on age or specific co-occurring conditions.

What the Research Landscape Does Not Yet Fully Address (Uncertainty)

While a substantial body of research exists, there are aspects of the combination's profile where evidence is limited or data are still emerging. Most controlled trials designed to explore short-term changes have follow-up durations were limited, and long-term outcomes are not fully established directly for this exact fixed-dose tablet. Specifically, there is limited information for long-term outcomes demonstrating direct patterns on major cardiovascular event rates using multi-year, large-scale studies of the fixed combination product. These research limitation frames mean that study results reflect the specific conditions and populations under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Stamlo D (FAQ)


Q: What happens if I stop taking Stamlo D suddenly?

Official warnings related to the amlodipine component indicate that problems like worsening chest pain (angina) or a heart attack can occur after starting or increasing the dose, particularly in patients with severe heart artery disease. Official warnings emphasize that any changes to the therapy, including discontinuation, should be medically supervised to minimize risk.


Q: Is it normal to feel dizzy or tired when starting Stamlo D?

Regulatory documents list dizziness and fatigue as common adverse reactions (occurring in at least 2% of patients) observed during clinical trials. This indicates that these effects may be experienced by some patients when starting the medication.


Q: Does Stamlo D cause frequent urination because of the diuretic component?

The Hydrochlorothiazide component is a diuretic. Its mechanism of action is intended to increase the output of water and electrolytes, which results in increased production of urine.


Q: Are there any specific foods or drinks I should avoid while on Stamlo D?

The official warnings indicate that Grapefruit or Grapefruit Juice may increase the amount of the amlodipine component absorbed, which could increase the risk of low blood pressure. Other foods are not specifically prohibited in the label.


Q: Is it safe to take over-the-counter pain relievers like Ibuprofen with Stamlo D?

The labels warn that taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which includes common pain relievers like Ibuprofen, may reduce the blood pressure-lowering effect. Furthermore, this combination may increase the risk of kidney impairment. The official labels indicate that this co-administration requires caution and should be medically reviewed.


Q: Can I take multivitamins or supplements while using Stamlo D?

While the label does not prohibit all multivitamins, caution is advised with supplements containing potassium, as the hydrochlorothiazide component can affect the body's electrolyte balance. All supplements should be medically reviewed for potential interactions.


Q: Does Stamlo D have any long-term side effects that I should worry about?

Official warnings mention that increased risk of Non-melanoma skin cancer is associated with long-term exposure and cumulative doses of the hydrochlorothiazide component. Due to this and other potential long-term risks, ongoing medical review is necessary.


Q: Does Stamlo D cause swelling in the ankles or feet?

Peripheral edema (swelling) is a frequently reported adverse reaction associated with the amlodipine component, as documented in clinical trials. This is a common effect experienced by some patients.


Q: Why do some people say they have a dry cough from blood pressure medicine, and does Stamlo D cause this?

A dry cough is a known potential side effect of a different class of blood pressure medicines (ACE inhibitors). Regulatory documents for Stamlo D (Amlodipine/Hydrochlorothiazide) do not list a dry cough as a common or generally reported adverse reaction observed in clinical trials.


Q: Can Stamlo D be taken on an empty stomach?

According to the official dosing and administration instructions, the tablet may be administered with or without food.


Q: Is Stamlo D considered a safe medication for long-term use?

Official information highlights the need for caution, noting that increased risk of Non-melanoma skin cancer is associated with long-term exposure to the hydrochlorothiazide component. Additionally, research summaries note that long-term outcomes are not fully established directly for this fixed-dose tablet.


Q: Are there any physical activities to avoid while taking Stamlo D?

The regulatory information includes warnings about the potential for symptomatic hypotension (low blood pressure) and electrolyte imbalance. Activities that cause excessive dehydration or heat exposure may increase this risk and should be discussed with a healthcare provider.


Q: Is it normal to feel a mild headache after taking Stamlo D?

Yes, headache is specifically listed in regulatory documents as a common adverse reaction (occurring in at least 2% of patients) observed during clinical trials. This suggests that a mild headache is a possible effect when starting the medication.


Q: Does Stamlo D affect heart rate?

While its primary goal is blood pressure control, regulatory warnings for the amlodipine component indicate that it can rarely be associated with changes in heart rate, particularly upon initiating the dose or increasing it.


Q: Does Stamlo D cause weight gain or loss?

Weight changes are not explicitly listed as a common side effect in the regulatory documents. However, the common side effect of edema (swelling/fluid retention) may cause fluctuations in body weight.


Q: Does Stamlo D make people sensitive to the sun?

Yes, the hydrochlorothiazide component is associated with photosensitivity (increased sensitivity to sunlight). The official label advises patients to protect their skin from sun exposure.


Q: Does Stamlo D affect cholesterol levels?

Postmarketing reports for the hydrochlorothiazide component include mentions of increased blood lipids (fats like cholesterol and triglycerides) as a possible adverse reaction. This suggests potential relevance to metabolic markers.


Q: Does Stamlo D cause changes in mood or anxiety?

Changes in mood or anxiety are not listed as common side effects observed during clinical trials. However, postmarketing experience for the amlodipine component includes general reports related to the nervous system.


Q: How quickly should I expect Stamlo D to start lowering my blood pressure?

The official dosing protocol indicates that the full blood pressure lowering effect may take a minimum of two weeks to fully manifest. Therefore, doses are typically only adjusted after this period to allow the medication time to achieve its full therapeutic action.


Q: What are the most common but mild side effects of Stamlo D?

According to official regulatory documents, the most common adverse reactions (occurring in at least 2% of patients) include peripheral edema (swelling), headache, dizziness, fatigue, and nasopharyngitis.


Q: Is it necessary to monitor potassium levels while taking Stamlo D?

Yes, regulatory documents indicate that the Hydrochlorothiazide component carries a documented risk of disturbances in fluid and electrolyte balance, including hypokalemia (low potassium). Monitoring serum electrolytes is often a necessary step.


Q: What should I do if I accidentally miss a dose of Stamlo D?

Regulatory patient information typically advises that if a dose is missed, it should be taken as soon as possible, but if it is almost time for the next scheduled dose, the missed dose should be skipped. It is specifically advised not to take a double dose.


Q: What are the signs that Stamlo D is actually working?

A measured reduction in Systolic and Diastolic Blood Pressure (SBP/DBP) readings is the key indicator, observed in clinical studies, that the medication is achieving its intended therapeutic goal.


Q: Is it true that Stamlo D can help reduce fluid retention?

The diuretic component's mechanism of action involves increasing the output of water and electrolytes through the kidneys. This process results in a reduction of plasma volume and helps manage fluid retention.


Q: Can I drink alcohol in moderation while taking Stamlo D?

Official regulatory warnings advise that co-administration with alcohol is documented to increase the risk of orthostatic hypotension (a sudden drop in blood pressure when changing positions). This indicates that caution may be needed when consuming alcohol.


Q: How long does the effect of one Stamlo D tablet last?

The official administration instructions state that the combination product is to be taken once daily. This dosing schedule implies that the therapeutic effects of the active components are sustained over a 24-hour period.


Q: What if my blood pressure still seems high after starting Stamlo D?

The official dosing protocol indicates that the full therapeutic effect may take a minimum of two weeks to fully manifest. If blood pressure remains high beyond this period, it is a signal that further medical review may be needed to determine if an adjustment is appropriate.


Q: How is Stamlo D different from other blood pressure medications that contain a diuretic?

Stamlo D is a fixed-dose combination that pairs a Calcium Channel Blocker (Amlodipine) with a Thiazide Diuretic (Hydrochlorothiazide). This is a specific pairing that distinguishes it from other combination medications that may use a diuretic with a different class, such as an ACE inhibitor or an ARB.


Q: What is the risk of electrolyte imbalance with Stamlo D?

The Hydrochlorothiazide component carries a documented risk of disturbances in fluid and electrolyte balance. This includes the potential for low levels of potassium (hypokalemia), sodium (hyponatremia), and chloride (hypochloremic alkalosis).


Q: Is Stamlo D a common first-line treatment for high blood pressure?

Official product labeling states that this product is not indicated for the initial treatment of high blood pressure (hypertension). It is typically reserved for patients who need either replacement therapy or an add-on therapy because their blood pressure is not adequately controlled with other single-agent regimens.


Q: Why is it important to check my blood pressure regularly when taking Stamlo D?

Regular blood pressure monitoring is important because the drug’s effectiveness is solely determined by measuring the reduction in blood pressure readings. The official dosing protocol requires a minimum of two weeks of monitoring to inform any decision regarding a change in dosage.

How should Stamlo D be stored and disposed of?

How to Store and Dispose of Stamlo D

Stamlo D (Amlodipine/Hydrochlorothiazide) must be stored under specific environmental conditions to maintain stability, as dictated by regulatory labeling.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted to 30 C.
Protection Protect from moisture and excessive heat; do not freeze.
Container Keep in the original container and maintain it tightly closed.

The product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Stamlo D should be disposed of in the household trash, following official government guidance for non-flushing medicines. This involves mixing the product with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a container before discarding it. Do not flush the tablets down the toilet or pour them down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Stamlo D found in:

A-Z Index: